DDInter717 DDInter1628
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Tolterodine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Tolterodine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Donepezil {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Donepezil {u} (Compound) upregulates {v} (Gene) PRKAG2
PRKAG2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Argatroban
Argatroban {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Acarbose {u} (Compound) downregulates {v} (Gene) OSBPL10
OSBPL10 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) upregulates PRKAG2 (Gene) and PRKAG2 (Gene) is downregulated by Ruxolitinib (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Ruxolitinib (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose (Compound) downregulates OSBPL10 (Gene) and OSBPL10 (Gene) is downregulated by Ruxolitinib (Compound)